Story
High Tide Stock Declines as Record Earnings Trigger Profit-Taking

Summary
Shares of cannabis retailer High Tide fell Friday in a classic "sell the news" reaction, as investors locked in gains following a record-breaking third-quarter earnings report that far surpassed analyst expectations.
High Tide Inc. (HITI) shares fell more than 5% on Friday, trading at C$3.49 despite the company reporting exceptionally strong third-quarter results. The decline suggests investors are taking profits after a run-up in the stock, a market dynamic often referred to as "sell the news," which was compounded by a broader downturn in major stock indexes.
A Record-Breaking Quarter
In its fiscal third-quarter 2026 earnings report, released after Thursday's market close, High Tide announced results that significantly beat analyst consensus across key metrics. The performance highlighted material improvement in the company's underlying business fundamentals.
- Revenue: Reached a record C$199 million, a 33% increase year-over-year and approximately 45% above analyst forecasts.
- Adjusted EBITDA: Climbed 53% to a record C$16.2 million, marking the company's highest margin in twelve quarters.
- Net Income: Hit a record C$12.7 million.
- Adjusted EPS: Came in at C$0.12, beating estimates by C$0.11.
Market Reaction and Context
AdDespite the magnitude of the earnings beat, the stock's trajectory on Friday points to a classic profit-taking scenario where positive results were largely priced in ahead of the announcement. The stock opened at its session high of C$3.70 before retreating throughout the day.
The selling pressure was exacerbated by a weak macroeconomic environment, with the S&P 500, Nasdaq, and Dow Jones all trading lower. This risk-off sentiment often disproportionately affects higher-beta, small-cap stocks like High Tide. The stock remains significantly below its 52-week high of C$5.59, reflecting ongoing valuation concerns for Canadian cannabis retailers amid sector-wide softness in consumer spending.
Analyst View Unchanged
Following the report, Canaccord Genuity reiterated its Buy rating and C$7.50 price target for High Tide. The firm cited strong operating leverage and the continued growth of Remexian, the company’s German medical cannabis subsidiary, as key drivers. However, this analyst support was not enough to overcome the selling pressure during Friday's trading session.
Read next
More on Stocks
UBS Upgrades UK Equities to 'Attractive' on Energy Price Surge and Valuation
The investment bank raised its outlook for UK stocks following a recent pullback, citing strong earnings potential from rising energy prices and setting higher targets for the FTSE 100.

Nikkei 225 Rises 1.52% to Close Week on Sector Strength
Japan's benchmark Nikkei 225 index closed significantly higher on Friday, gaining 1.52% as advances in real estate, banking, and technology shares lifted the market.

Citi Reaffirms Amazon as Top Pick, Sees FTC Lawsuit as Buying Opportunity
Analysts at Citi maintained a Buy rating and a $350 price target on Amazon, advising investors to look past an FTC advertising lawsuit and focus on accelerating AI demand and retail market share gains.

European Stocks End Two-Week Losing Streak on Fed's Inflation Stance
The pan-European Stoxx 600 is poised for its first weekly gain in three, rebounding from multi-month lows after the U.S. Federal Reserve's interest rate hike reassured investors of its commitment to controlling inflation.